BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta

On June 13, 2022

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Federal Realty Investment Trust Announces Second Quarter 2022 Earnings Release Date and Conference Call Information

Mattel Announces Second Quarter 2022 Financial Results Conference Call

KLA Corporation Announces Pricing of Tender Offer